Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

Published 2013 View Full Article

Authors

Keywords

Journal

LANCET ONCOLOGY

Volume 14, Issue 6, Pages 481-489

Publisher

Elsevier BV

Online

2013-04-17

DOI

10.1016/s1470-2045(13)70096-2

Ask authors/readers for more resources

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started

LANCET ONCOLOGY

Ask authors/readers for more resources

Protocol

Reagent

Reprint

Find Funding. Review Successful Grants.

Ask a Question. Answer a Question.